Editas Medicine Inc (EDIT)

05:53 AM

Chardan Capital Reiterates Buy Rating for Editas Medicine (NASDAQ:EDIT) - MarketBeat

05:53 AM

04:19 AM

Chardan Capital Markets Reiterates Buy Rating on Editas Medicine (EDIT) - StreetInsider.com

04:19 AM

02:38 AM

Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty - GuruFocus.com

02:38 AM

01:12 AM

Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y - MSN

01:12 AM

01:06 AM

Editas Medicine maintains Perform rating at Oppenheimer By Investing.com - Investing.com UK

01:06 AM

10:18 AM

Editas Medicine (NASDAQ:EDIT) Price Target Lowered to $5.00 at Barclays - MarketBeat

10:18 AM

09:00 AM

Editas Medicine (NASDAQ:EDIT) Announces Quarterly Earnings Results - MarketBeat

09:00 AM

05:43 AM

Editas Medicine Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

05:43 AM

05:26 AM

Editas Medicine (EDIT) PT Lowered to $5 at Barclays - StreetInsider.com

05:26 AM

04:01 AM

Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates - MSN

04:01 AM

01:45 AM

Truist cuts Editas Medicine target to $8, keeps buy rating By Investing.com - Investing.com Canada

01:45 AM

Nov 04, 2024

Editas Medicine Reports Q3 2024 Results and Developments - TipRanks

Nov 04, 2024

Nov 04, 2024

Editas downgraded to market perform by Raymond James - MSN

Nov 04, 2024

Nov 04, 2024

Editas downgraded to market perform by Raymond James (NASDAQ:EDIT) - Seeking Alpha

Nov 04, 2024

Nov 04, 2024

Editas Medicine (NASDAQ:EDIT) Stock Rating Lowered by Raymond James - MarketBeat

Nov 04, 2024

Nov 04, 2024

Editas Medicine (EDIT) PT Lowered to $8 at Truist Securities - StreetInsider.com

Nov 04, 2024

Nov 04, 2024

Editas Medicine earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada

Nov 04, 2024

Nov 04, 2024

Editas: Q3 Earnings Snapshot - The Washington Post

Nov 04, 2024

Nov 04, 2024

Editas Medicine Announces Third Quarter 2024 Results and Business Updates - The Manila Times

Nov 04, 2024

Nov 01, 2024

Editas Medicine stock hits 52-week low at $2.9 amid market challenges - Investing.com Australia

Nov 01, 2024

Oct 31, 2024

Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock? - Yahoo Finance

Oct 31, 2024

Oct 30, 2024

10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds - Insider Monkey

Oct 30, 2024

Oct 30, 2024

Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Update - MarketBeat

Oct 30, 2024

Oct 29, 2024

Editas’ new gene-editing strategy for SCD shows promise in mice - Sickle Cell Disease News

Oct 29, 2024

Oct 28, 2024

In vivo editing data advances lift hopes for better access - BioCentury

Oct 28, 2024

Oct 28, 2024

FY2024 EPS Estimate for Editas Medicine Lifted by Analyst - MarketBeat

Oct 28, 2024

Oct 25, 2024

Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to Decline - Yahoo Finance

Oct 25, 2024

Oct 24, 2024

Petri Dish: GSK partners with BU; Be Biopharma enters clinic - The Business Journals

Oct 24, 2024

Oct 23, 2024

EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down - Yahoo Finance

Oct 23, 2024

Oct 23, 2024

Evercore ISI Cuts Editas Medicine (NASDAQ:EDIT) Price Target to $3.00 - MarketBeat

Oct 23, 2024

Oct 23, 2024

Expert Outlook: Editas Medicine Through The Eyes Of 7 Analysts - Benzinga

Oct 23, 2024

Oct 23, 2024

Editas Medicine achieves in vivo preclinical proof of concept of HSPC editing - BioWorld Online

Oct 23, 2024

Oct 23, 2024

Editas Medicine (EDIT) PT Lowered to $9 at Wells Fargo - StreetInsider.com

Oct 23, 2024

Oct 23, 2024

Editas advances gene editing treatment for blood disorders By Investing.com - Investing.com Australia

Oct 23, 2024

Oct 23, 2024

Editas advances gene editing treatment for blood disorders - Investing.com India

Oct 23, 2024

Oct 22, 2024

Chardan Capital Lowers Editas Medicine (NASDAQ:EDIT) Price Target to $12.00 - MarketBeat

Oct 22, 2024

Oct 22, 2024

Possible Signal As Editas Medicine Insiders Sell US$1.2m In Stock - Simply Wall St

Oct 22, 2024

Oct 22, 2024

Baird cuts Editas Medicine target to $10 from $18 By Investing.com - Investing.com UK

Oct 22, 2024

Oct 22, 2024

Editas Medicine Seeks Partner for Ex Vivo Gene-Editing Program as Focus Turns to In Vivo R&D - MedCity News

Oct 22, 2024

Oct 22, 2024

Editas, changing course again, looks to partner lead CRISPR therapy - BioPharma Dive

Oct 22, 2024

Oct 22, 2024

Editas and Genevant team up to develop gene editing therapies - Pharmaceutical Technology

Oct 22, 2024

Oct 22, 2024

EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies - Yahoo Finance

Oct 22, 2024

Oct 22, 2024

Editas stock slips on plans for gene editing drug (EDIT:NASDAQ) - Seeking Alpha

Oct 22, 2024

Oct 22, 2024

Editas Medicine Announces Progress Towards 2024 Goals, - GlobeNewswire

Oct 22, 2024

Oct 22, 2024

Editas Medicine, Inc. Announces Achievement of in Vivo Preclinical Proof of Concept - Marketscreener.com

Oct 22, 2024

Oct 22, 2024

Editas Medicine (EDIT) Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update - StreetInsider.com

Oct 22, 2024

Oct 22, 2024

Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update - StockTitan

Oct 22, 2024

Oct 21, 2024

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics - GlobeNewswire

Oct 21, 2024

Oct 18, 2024

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept - The Manila Times

Oct 18, 2024

Oct 18, 2024

Editas Medicine to Host Strategic Update Webinar to Detail - GlobeNewswire

Oct 18, 2024

Oct 18, 2024

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, ... - The Bakersfield Californian

Oct 18, 2024